Direct Healthcare Professional Communication (DHPC) on donepezil: QTc interval prolongation and torsade de pointes
2021.12.13
Active substance: donepezil
The marketing authorization holders of donepezil-containing drugs inform that post-marketing cases of QTc interval prolongation and torsade de pointes have been reported in association with the use of donepezil. Caution should be exercised in patients who have existing or family history of QTc interval prolongation, concomitant treatment with drugs that affect the QTc interval, or relevant cardiac disease.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN